Introduction
Status epilepticus (SE) is characterized by either prolonged epileptic seizure activity lasting at least 30 min or the occurrence of recurrent seizures between which baseline neurological status is not recovered. Although anticonvulsant treatments, such as benzodiazepines, phenytoin, valproate or phenobarbital, are remarkably efficient in SE, pharmacological resistance is observed in approximately 30% of patients. 1 For resistant patients, secondline treatments, including anesthetic drugs, such as propofol, midazolam or pentobarbital, are usually required to suppress seizures. Despite the availability of these efficient treatments, SE still shows a high mortality rate in adults, reaching up to 22%. This is particularly true when SE is associated with a long duration, very young or advanced age, encephalitic etiology or high morbidity. [1] [2] [3] Therefore, refractory SE remains a daily challenge for which our current therapeutic strategies fall short. Electroconvulsive therapy (ECT) is a well-known treatment that is used daily in several psychiatric disorders. It consists of applying electrical stimulation to the brain under mild anesthesia, accompanied by an electrical fit. ECT is markedly efficient, safe and may be life-saving for people who suffer from refractory mood disorders or schizophrenia. 4 The main side effect of ECT, objective memory impairment, is generally reversible, although a small proportion of ECT patients complain of persisting memory difficulties following treatment. 5, 6 The use of ECT in refractory epilepsy and SE is mentioned in psychiatry practice guidelines. 7 However, this treatment is rarely used in daily practice and remains poorly assessed in refractory SE. Only a few case reports have discussed the efficacy of ECT in refractory SE. Here, we provide a brief overview of those case reports to highlight some recommendations for the assessment and use of ECT in refractory SE.
Materials and methods
The MEDLINE database was searched without limits on the year of publication through February 2012 using the keyword combination of ''electroconvulsive therapy'' and any of the following terms: ''status epilepticus'', ''intractable epilepsy'', ''refractory status epilepticus'', ''malignant status epilepticus'', ''epilepsy'' and ''seizure''. Articles related to the cure of epilepsy were excluded to focus this review specifically on status epilepticus. All identified abstracts were read by two independent Refractory status epilepticus (SE) is a current daily therapeutic challenge. Electroconvulsive therapy (ECT), which is frequently used to treat psychiatric disorders, is known to raise the seizure threshold. As such, ECT could be of major interest in refractory SE. In this paper, we provide a brief overview of ECT in refractory SE. Although no placebo-controlled or open-label study has been published on the efficacy or safety of ECT in refractory SE, eight case reports have been identified. SE cessation was obtained in 80% of cases, and complete recovery was achieved in 27% of patients. Despite the heterogeneity of the ECT parameters used in these articles, we identified some common features that may be recommended for the use of ECT in refractory SE. ECT might be a viable therapeutic strategy for the most resistant and severe cases of SE, particularly after the failure of two inductions of anesthetic coma. This potential indication highlights the urgent need for clinical trials that assess the usefulness of ECT in refractory SE.
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investigators (VL and JYR) to select all relevant articles, reviews and case reports. The reference lists of these papers were also screened to optimize our bibliographic search.
Results
Neither double-blind nor open-label studies assessing ECT in refractory SE were found. Eight case reports were identified, including 11 patients with refractory SE treated by ECT. The results from these case reports are summarized in Table 1 . After the clinical description of these reports, we will present the ECT parameters used for each patient.
Case reports
Although ECT has been used to treat epilepsy since the 1930s, 8, 9 the first case reports discussing the use of ECT in refractory SE were published in the 1990s. The initial ECT treatment was planned for the 103rd day after the onset of seizures. Pharmacological treatments were continued during ECT treatment. The first ECT session provoked a marked decrease in spike activity, and two more sessions in the following days resulted in the termination of SE. The patient's seizure activity gradually decreased for sixteen months after ECT, although some focal seizures persisted sporadically and were associated with cognitive decline. Three cases were described by Kamel et al., 16 and ECT-related improvement was obtained in two patients. The three patients were admitted with SE consecutive to viral encephalitis. The first patient was a 32-year-old woman who had successively received usual therapeutic strategies for SE, including propofol, midazolam, prednisolone, pentobarbital and ketamine, with no improvement. Three trials of pentobarbital were performed to achieve complete burst suppression without efficacy. ECT was started six weeks after the onset of seizures, without anticonvulsant discontinuation. Propofol and midazolam were given between sessions to maintain burst suppression. Four sessions were performed over a period of five days and led to clinical and electroencephalographic improvement. She complained of short retrograde amnesia and anterograde amnesia that disappeared after the remission of viral encephalitis. The second patient was a 41-year-old woman. Similar therapeutic strategies and the same protocol of four daily cycles of ECT were performed thirty days after the onset of SE. However, ECT alone was not efficient in this case. The addition of pentobarbital concomitant with ECT treatment led to electroencephalographic suppression. Unfortunately, after several days of pentobarbital infusions, multiple complications (nosocomial infection and renal failure) occurred, and the patient died. The third patient was a 26-year-old woman in whom ECT was performed two months after the onset of SE according to the same protocol. Despite a therapeutic strategy including pentobarbital-induced coma, ketamine, isoflurane and high doses of methylprednisolone, the first two ECT sessions failed to provoke a generalized electrographic seizure. The third session succeeded after midazolam was withdrawn. SE completely stopped after the eighth session of ECT. Nonetheless, some seizures remained, resulting in mild difficulties with short-term memory and concentration. Shin et al. 17 reported the case of a 7-year-old girl with nonconvulsive SE secondary to bilateral polymicrogyria who was treated with valproate, levetiracetam and clobazam. Anesthetic coma with burst suppression was obtained with a combination of midazolam, pentobarbital, ketamine, topiramate and steroids. ECT was started on the 14th day after the onset of seizures, during which pharmacological treatments were continued, except for pentobarbital and ketamine, and midazolam was exchanged with flumazenil prior to each session. The first two ECT sessions were performed on consecutive days and resulted in a cessation of nonconvulsive SE within 6 h of treatment. Two days later, nonconvulsive SE symptoms returned. Six more ECT sessions were necessary over the course of the next week to definitively terminate SE. This was achieved with generalized slowing and bihemispheric periodic lateralized epileptiform discharges in EEG.
Discussion
After the failure of drug therapies, physical treatments may be considered for refractory SE. In the last decades, many physical treatments have been discussed for refractory SE, such as transcranial magnetic stimulation, vagal nerve stimulation, deep brain stimulation or cerebrospinal fluid drainage. Up to date, ECT remains the most -but still poorly -assessed physical treatment. 18, 19 Our overview of case reports suggests that ECT may be of interest in some refractory and severe cases of SE. In the 11 patients (7 adults and 4 children) with refractory SE treated with ECT described in the literature, ECT prevented SE in 80% of cases, although full functional recovery was described in only three patients (27%). In these patients, ECT was delivered 30-40 days after the onset of SE. In contrast, the occasional persistence of seizures (four patients, 36%) or presence of minor cognitive impairment (two patients, 18%) may be explained by either the delayed use of ECT 15, 16 or the specific etiology of SE in these instances, such as cortical dysplasia 12, 13 or ceroid lipofuscinosis.
14 Three patients (27%) succumbed to death, although this was essentially due to the occurrence of medical complications and not directly related to the use of ECT. Of practical importance is the concern that the ECT parameters and protocols used in these articles were heterogeneous, although some parameters were similar. First, although anti-epileptic drugs were most often continued during ECT, this pharmacological treatment could be adapted to promote ECT-induced seizures. For example, treatments such as midazolam could be reduced or stopped to reduce the seizure threshold. Consistent with this idea, some authors have also proposed using flumazenil 15 min before each ECT session. Second, ECT sessions were generally administered in the month following the onset of SE. It is difficult to assess the impact of the duration of uncontrolled SE on ECT efficacy; however, one can reasonably assume that ECT might be more effective when administered at the earliest possible stage. For example, the effectiveness of ECT might be improved when used in the days immediately following the identification of pharmacological resistance. Likewise, early treatment might reduce the risk of SE complications. However, as described by Kamel et al. 16 and
Shorvon and Ferlisi 18 ECT has to be administered only in superrefractory SE cases, especially after the failure of at least two trials of anesthetic coma with the maintenance of prior antiepileptic drugs. Third, the frequency of ECT reported in these studies was commonly scheduled between two and four sessions a week until clinical or electroencephalographic improvement, which was generally achieved during the first ten days of treatment. The number of sessions and duration of ECT were individualized for each patient according to the evolution of the clinical and electroencephalographic assessments. In most cases, subsequent pharmacological treatments were used to efficiently maintain SE remission after ECT cessation. Finally, a range of different ECT electrode placements were tried by the authors, of which the common placements were bitemporal or bifrontocentral. Concerning the physiopathology, the anti-epileptic effects of ECT are based on increased GABAergic transmission and the prolongation of the refractory period after a seizure. 20 ECT raises the seizure threshold by activating the inhibitory mechanisms needed to abort a seizure. ECT has potent anti-convulsant properties that are shared with the anti-convulsant drugs used in the treatment and prophylaxis of bipolar disorder, one of the main indicators for the use of ECT in psychiatry. For example, an enhanced seizure threshold was observed in 21% of patients with severe mood disorder after ECT. 21 It has been proposed that ECT can activate the inhibitory mechanisms required to abort a seizure by inducing generalized seizure, especially by modulating GABAergic transmission. However, ECT is also known to modulate all mono-aminergic pathways. Regardless, the mechanism by which ECT is effective against SE and mood disorders remains to be elucidated.
In conclusion, 11 case reports have been published assessing the safety and efficacy of ECT in refractory status epilepticus. This review of case reports succeeded in the identification of common ECT parameters used in this very specific indication of refractory status epilepticus. Although based on a small number of cases, our review suggested that electroconvulsive therapy was effective for many patients with refractory status epilepticus. Thus, beyond all a priori ideas, electroconvulsive therapy could be considered in the treatment algorithm for refractory status epilepticus, particularly after the failure of two inductions of anesthetic coma. Improved neurological outcomes might be achieved with protocols that include ECT after inducing a barbiturate coma but before irreversible brain damage has occurred. Therefore, to confirm this conclusion, case reports and open-label clinical trials on the use of electroconvulsive therapy in this indication should be conducted.
